GlassScriptPhysician profile
Yong Jun Kim
NPI 1073512950
$1,274.60
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $194 · 2021: $254 · 2022: $251.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $224.98 | 2019-2022 | |
| Nuvasive, INC. | $180.71 | 2021-2022 | |
| Gilead Sciences, INC. | $174.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $141.35 | 2020-2021 | |
| Novo Nordisk INC | $124.43 | 2019-2020 | |
| Lilly USA, LLC | $102.94 | 2019-2020 | |
| Amarin Pharma, INC. | $95.81 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $64.39 | 2019 | |
| Daiichi Sankyo INC. | $44.73 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.74 | 2019 | |
| Pfizer INC. | $32.52 | 2019 | |
| Genzyme Corporation | $20.00 | 2021 | |
| Allergan, INC. | $16.52 | 2019 | |
| Merck Sharp & Dohme LLC | $15.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.